1008 related articles for article (PubMed ID: 14500907)
1. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
Kleer CG; Cao Q; Varambally S; Shen R; Ota I; Tomlins SA; Ghosh D; Sewalt RG; Otte AP; Hayes DF; Sabel MS; Livant D; Weiss SJ; Rubin MA; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11606-11. PubMed ID: 14500907
[TBL] [Abstract][Full Text] [Related]
2. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
Karanikolas BD; Figueiredo ML; Wu L
Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877
[TBL] [Abstract][Full Text] [Related]
3. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast.
Ding L; Kleer CG
Cancer Res; 2006 Oct; 66(19):9352-5. PubMed ID: 17018586
[TBL] [Abstract][Full Text] [Related]
5. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements.
Tonini T; D'Andrilli G; Fucito A; Gaspa L; Bagella L
J Cell Physiol; 2008 Feb; 214(2):295-300. PubMed ID: 17786943
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
7. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.
Shi B; Liang J; Yang X; Wang Y; Zhao Y; Wu H; Sun L; Zhang Y; Chen Y; Li R; Zhang Y; Hong M; Shang Y
Mol Cell Biol; 2007 Jul; 27(14):5105-19. PubMed ID: 17502350
[TBL] [Abstract][Full Text] [Related]
8. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
9. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A
Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305
[TBL] [Abstract][Full Text] [Related]
10. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A.
Tonini T; Bagella L; D'Andrilli G; Claudio PP; Giordano A
Oncogene; 2004 Jun; 23(28):4930-7. PubMed ID: 15077161
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
12. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
Zeidler M; Kleer CG
J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786
[TBL] [Abstract][Full Text] [Related]
13. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
Cho KS; Oh HY; Lee EJ; Hong SJ
Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
[TBL] [Abstract][Full Text] [Related]
14. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.
Lee ST; Li Z; Wu Z; Aau M; Guan P; Karuturi RK; Liou YC; Yu Q
Mol Cell; 2011 Sep; 43(5):798-810. PubMed ID: 21884980
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
Fujii S; Ochiai A
Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
[TBL] [Abstract][Full Text] [Related]
16. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
17. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.
Zeidler M; Varambally S; Cao Q; Chinnaiyan AM; Ferguson DO; Merajver SD; Kleer CG
Neoplasia; 2005 Nov; 7(11):1011-9. PubMed ID: 16331887
[TBL] [Abstract][Full Text] [Related]
18. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
Hwang C; Giri VN; Wilkinson JC; Wright CW; Wilkinson AS; Cooney KA; Duckett CS
Breast Cancer Res Treat; 2008 Jan; 107(2):235-42. PubMed ID: 17453341
[TBL] [Abstract][Full Text] [Related]
19. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.
Granit RZ; Gabai Y; Hadar T; Karamansha Y; Liberman L; Waldhorn I; Gat-Viks I; Regev A; Maly B; Darash-Yahana M; Peretz T; Ben-Porath I
Oncogene; 2013 Aug; 32(33):3886-95. PubMed ID: 22986524
[TBL] [Abstract][Full Text] [Related]
20. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]